Tonix Pharmaceutical (TNXP) skyrockets Friday and will continue Monday
For starters, the reasoning for the tremendous gains is due to an SEC filing where the company said that it will present information concerning TNX-1800. The candidate is being developed as a potential COVID-19 vaccine. Based on the company’s horse pox vector, the TNX-1800 was developed. The presentation will take place at the World Health Organization on March 20, 2020. TNXP said that the presentation may include nonpublic information and is filed as Exhibit 99.01 with the SEC. This information makes investors excited for one reason, the COVID-19 vaccine. With COVID-19 growing worse by the week proving that it can be fatal, some expect it to kill millions. The demand for a vaccine is very high and Tonix could be into something big. The filing is nothing to look past and if the data proves to be as meaningful as it seems, the opportunity for Tonix could be incredible.